CY1122717T1 - Ανασυνδυασμενος τροποπoiημενος ιος της δαμαλιτιδας της αγκυρας (mva) ως εμβολιο εναντι του αναπνευστικου συγκυτιακου ιου (rsv) - Google Patents
Ανασυνδυασμενος τροποπoiημενος ιος της δαμαλιτιδας της αγκυρας (mva) ως εμβολιο εναντι του αναπνευστικου συγκυτιακου ιου (rsv)Info
- Publication number
- CY1122717T1 CY1122717T1 CY20201100050T CY201100050T CY1122717T1 CY 1122717 T1 CY1122717 T1 CY 1122717T1 CY 20201100050 T CY20201100050 T CY 20201100050T CY 201100050 T CY201100050 T CY 201100050T CY 1122717 T1 CY1122717 T1 CY 1122717T1
- Authority
- CY
- Cyprus
- Prior art keywords
- rsv
- virus
- mva
- rosive
- against respiratory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/065—Poxviridae, e.g. avipoxvirus
- C07K14/07—Vaccinia virus; Variola virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18571—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Στο παρόν έγγραφο παρέχονται ανασυνδυασμένα τροποποιημένα στελέχη του ιού της δαμαλίτιδας της ¶γκυρας (MVA) ως βελτιωμένα εμβόλια έναντι λοίμωξης από τον αναπνευστικό συγκυτιακό ιό (ιός RSV) και συναφή προϊόντα, μέθοδοι και χρήσεις. Συγκεκριμένα, στο παρόν έγγραφο παρέχονται γενετικά τροποποιημένοι ανασυνδυασμένοι φορείς MVA που περιλαμβάνουν τουλάχιστον μία νουκλεοτιδική αλληλουχία που κωδικοποιεί έναν αντιγονικό καθοριστή μιας μεμβρανικής γλυκοπρωτεΐνης του RSV και τουλάχιστον μία νουκλεοτιδική αλληλουχία που κωδικοποιεί έναν αντιγονικό καθοριστή μιας νουκλεοκαψιδιακής πρωτεΐνης του RSV. Επίσης, στο παρόν έγγραφο παρέχονται προϊόντα, μέθοδοι και χρήσεις αυτών, π.χ., κατάλληλες να επηρεάζουν την ανοσοαπόκριση σε ένα υποκείμενο, ή κατάλληλες για τη διάγνωση της λοίμωξης από RSV, καθώς και για να προσδιοριστεί, εάν ένα υποκείμενο κινδυνεύει από επαναλαμβανόμενη λοίμωξη από RSV.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261678367P | 2012-08-01 | 2012-08-01 | |
EP12005594 | 2012-08-01 | ||
EP13717721.8A EP2879702B9 (en) | 2012-08-01 | 2013-03-15 | Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine |
PCT/EP2013/055483 WO2014019718A1 (en) | 2012-08-01 | 2013-03-15 | Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1122717T1 true CY1122717T1 (el) | 2021-03-12 |
Family
ID=46614287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100050T CY1122717T1 (el) | 2012-08-01 | 2020-01-21 | Ανασυνδυασμενος τροποπoiημενος ιος της δαμαλιτιδας της αγκυρας (mva) ως εμβολιο εναντι του αναπνευστικου συγκυτιακου ιου (rsv) |
Country Status (19)
Country | Link |
---|---|
US (6) | US9480738B2 (el) |
EP (2) | EP3656396A1 (el) |
JP (2) | JP6523955B2 (el) |
KR (3) | KR102435054B1 (el) |
CN (2) | CN109266622B (el) |
AU (1) | AU2013298915B2 (el) |
BR (1) | BR112015002131B1 (el) |
CA (2) | CA2879915C (el) |
CY (1) | CY1122717T1 (el) |
EA (2) | EA201891945A3 (el) |
HK (1) | HK1205459A1 (el) |
IL (1) | IL236744B (el) |
IN (1) | IN2015DN01448A (el) |
MX (3) | MX362511B (el) |
MY (1) | MY171498A (el) |
NZ (1) | NZ704005A (el) |
SG (1) | SG11201500696VA (el) |
SI (1) | SI2879702T1 (el) |
WO (1) | WO2014019718A1 (el) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2879702T3 (da) * | 2012-08-01 | 2020-02-24 | Bavarian Nordic As | Rekombinant modificeret vacciniavirus ankara (mva)-vaccine mod respiratorisk syncytialvirus (rsv) |
AU2014231229A1 (en) * | 2013-03-15 | 2015-09-17 | Bavarian Nordic A/S | Single high dose of MVA induces a protective immune response in neonates and infants |
EP3154576A1 (en) | 2014-06-13 | 2017-04-19 | GlaxoSmithKline Biologicals S.A. | Immunogenic combinations |
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
JP6983665B2 (ja) | 2015-06-12 | 2021-12-17 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | アデノウイルスポリヌクレオチド及びポリペプチド |
FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
US11192926B2 (en) | 2017-04-04 | 2021-12-07 | University Of Washington | Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use |
CA3062549A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
CA3061678A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
EA202091178A1 (ru) | 2017-12-20 | 2020-09-01 | Глаксосмитклайн Байолоджикалс Са | Антигенные конструкции на основе вируса эпштейна-барр |
CA3095216A1 (en) | 2018-02-28 | 2019-09-06 | University Of Washington | Self-asssembling nanostructure vaccines |
WO2020049151A1 (en) | 2018-09-06 | 2020-03-12 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
US20220195016A1 (en) * | 2019-04-18 | 2022-06-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Biological and synthetic molecules inhibiting respiratory syncytial virus infection |
KR20220047332A (ko) * | 2019-08-13 | 2022-04-15 | 알티뮨 인크. | 치료제 효과 및 이의 투여 경로 |
BR112022017438A2 (pt) | 2020-03-12 | 2022-10-18 | Bavarian Nordic As | Composições que melhoram a estabilidade do poxvírus |
IL311078A (en) | 2021-09-03 | 2024-04-01 | Bavarian Nordic As | Use of microRNA to downregulate expression of cytotoxic transgenes by modified vicinia ankara virus (mva) |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US5149650A (en) | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
US5639853A (en) | 1987-09-29 | 1997-06-17 | Praxis Biologics, Inc. | Respiratory syncytial virus vaccines |
US5223254A (en) | 1987-09-29 | 1993-06-29 | Praxis Biologics, Inc. | Respiratory syncytial virus: vaccines |
ATE85622T1 (de) | 1987-12-23 | 1993-02-15 | Upjohn Co | Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus. |
CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
US6730305B1 (en) | 2000-05-08 | 2004-05-04 | The Uab Research Foundation | Nucleotide sequences encoding bovine respiratory syncytial virus immunogenic proteins |
WO1992001471A1 (en) | 1990-07-24 | 1992-02-06 | The Uab Research Foundation | Methods of use of bovine respiratory syncytial virus recombinant dna, proteins vaccines, antibodies, and transformed cells |
GB9200117D0 (en) | 1992-01-06 | 1992-02-26 | Connaught Lab | Production of recombinant chimeric proteins for vaccine use |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
AU710713B2 (en) | 1994-08-25 | 1999-09-30 | Stichting Instituut Voor Dierhouderij En Diergezondheid | Antigenic peptides derived from the G protein of RSV for type- and subtype-specific diagnosis of respiratory syncytial virus (RSV) infection |
FR2726471B1 (fr) | 1994-11-07 | 1997-01-31 | Pf Medicament | Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins |
US6083925A (en) | 1995-06-07 | 2000-07-04 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
US6019980A (en) | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
US6180398B1 (en) | 1996-07-12 | 2001-01-30 | Virogeneitics Corporation | Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation |
US6020182A (en) | 1996-07-12 | 2000-02-01 | Connaught Laboratories Limited | Subunit respiratory syncytial virus vaccine preparation |
FR2751229B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins |
US6699478B1 (en) | 1997-09-19 | 2004-03-02 | Wyeth Holdings Corporation | Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus |
FR2798857B1 (fr) * | 1999-09-23 | 2003-06-06 | Pf Medicament | Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale |
US6651655B1 (en) | 2000-01-18 | 2003-11-25 | Quadrant Technologies Limited | Inhaled vaccines |
GB0024089D0 (en) * | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
SG106639A1 (en) | 2000-10-10 | 2004-10-29 | Gen Electric | Apparatus and method for introducing small amounts of refractory elements into a vapor deposition coating |
AU2002224416A1 (en) | 2000-10-18 | 2002-04-29 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention | Compositions and methods for modulating RSV infection and immunity |
CN100537773C (zh) | 2000-11-23 | 2009-09-09 | 巴法里安诺迪克有限公司 | 改良安卡拉痘苗病毒变体 |
US6855493B2 (en) | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
FR2827605B1 (fr) | 2001-07-20 | 2004-07-16 | Pf Medicament | Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin |
KR101042458B1 (ko) | 2001-12-04 | 2011-06-16 | 벤처 테크놀로지스 에스디엔 비에이치디 | 플라비바이러스 ns1 서브유닛 백신 |
JP4895505B2 (ja) | 2002-05-16 | 2012-03-14 | バヴァリアン・ノルディック・アクティーゼルスカブ | 変異ワクシニアウイルスアンカラ(mva)ゲノム中の挿入部位としての遺伝子間領域 |
US7368537B2 (en) | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
EP1768993A4 (en) | 2004-06-16 | 2008-07-23 | Univ Johns Hopkins | CYSTEINE-RICH REGION OF SYNCYTIAL RESPIRATORY VIRUS AND METHODS OF USE THEREOF |
MX2007002372A (es) * | 2004-08-27 | 2007-05-08 | Panacea Biotec Ltd | Vacuna para la poliomielitis inactivada derivada de la cepa sabin del virus de la polio. |
US20120121650A1 (en) * | 2006-08-18 | 2012-05-17 | Johnston Robert E | Chimeric Virus Vaccines |
US8772256B2 (en) * | 2006-11-30 | 2014-07-08 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Codon modified immunogenic compositions and methods of use |
DE102006060799A1 (de) | 2006-12-21 | 2008-06-26 | RUHR-UNIVERSITäT BOCHUM | RSV F-Protein und seine Verwendung |
EP2181121A4 (en) | 2007-03-21 | 2012-07-11 | Id Biomedical Corp Quebec | CHIMÄRE ANTIGENE |
KR100938105B1 (ko) * | 2007-09-21 | 2010-01-21 | 이화여자대학교 산학협력단 | 호흡기 신시치아 바이러스 백신 |
DK2222710T3 (en) | 2007-12-24 | 2016-10-03 | Id Biomedical Corp Quebec | Recombinant RSV antigens. |
WO2010039224A2 (en) | 2008-09-30 | 2010-04-08 | University Of Massachusetts Medical School | Respiratory syncytial virus (rsv) sequences for protein expression and vaccines |
AU2009316680B2 (en) | 2008-11-18 | 2016-03-24 | Takeda Vaccines, Inc. | RSV F VLPs and methods of manufacture and use thereof |
CA2742247C (en) | 2008-11-21 | 2017-07-04 | Bavarian Nordic A/S | Vector comprising multiple homologous nucleotide sequences |
CN102307591B (zh) | 2008-12-09 | 2016-08-03 | 诺瓦瓦克斯股份有限公司 | 修饰的rsv f蛋白及其使用方法 |
US20110318376A1 (en) | 2008-12-24 | 2011-12-29 | University Of Rochester | Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins |
WO2010149743A2 (en) | 2009-06-24 | 2010-12-29 | Id Biomedical Corporation Of Quebec | Vaccine |
PE20121541A1 (es) | 2009-06-24 | 2012-12-21 | Glaxosmithkline Biolog Sa | Antigenos de virus de sincicio respiratorio recombinantes |
EP4218799A1 (en) * | 2009-07-15 | 2023-08-02 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
EP2461825B1 (en) | 2009-08-04 | 2017-05-31 | The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, | Anti-rsv immunogens and methods of immunization |
CN102695523A (zh) | 2009-09-10 | 2012-09-26 | 诺华有限公司 | 针对呼吸道疾病的组合疫苗 |
US20110097358A1 (en) | 2009-10-12 | 2011-04-28 | Techno Vax, Inc. | RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs) |
CA2777808C (en) | 2009-11-12 | 2015-01-13 | Trojan Technologies | Cleaning apparatus, radiation source module and fluid treatment system |
JP5783642B2 (ja) | 2010-01-28 | 2015-09-24 | バヴァリアン・ノルディック・アクティーゼルスカブ | Mvaの主なゲノム欠失を含むワクシニアウイルス変異体 |
AU2011276251B2 (en) * | 2010-07-07 | 2015-02-05 | Artifical Cell Technologies, Inc. | Respiratory syncytial virus antigenic compositions and methods |
WO2012080477A1 (en) * | 2010-12-17 | 2012-06-21 | Philip Morris Products S.A. | Container having interactive surface elements including design element |
WO2012085936A2 (en) | 2010-12-20 | 2012-06-28 | Panacea Biotech Ltd | Recombinant respiratory syncytial virus plasmids and vaccines |
WO2012089231A1 (en) * | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
-
2013
- 2013-03-15 EA EA201891945A patent/EA201891945A3/ru unknown
- 2013-03-15 SG SG11201500696VA patent/SG11201500696VA/en unknown
- 2013-03-15 MX MX2015001479A patent/MX362511B/es active IP Right Grant
- 2013-03-15 WO PCT/EP2013/055483 patent/WO2014019718A1/en active Application Filing
- 2013-03-15 JP JP2015524681A patent/JP6523955B2/ja active Active
- 2013-03-15 KR KR1020217017594A patent/KR102435054B1/ko active IP Right Grant
- 2013-03-15 MY MYPI2015700265A patent/MY171498A/en unknown
- 2013-03-15 CA CA2879915A patent/CA2879915C/en active Active
- 2013-03-15 EP EP19211547.5A patent/EP3656396A1/en not_active Withdrawn
- 2013-03-15 CN CN201811121036.XA patent/CN109266622B/zh active Active
- 2013-03-15 IN IN1448DEN2015 patent/IN2015DN01448A/en unknown
- 2013-03-15 US US14/417,779 patent/US9480738B2/en active Active
- 2013-03-15 EA EA201590304A patent/EA031453B1/ru not_active IP Right Cessation
- 2013-03-15 NZ NZ704005A patent/NZ704005A/en unknown
- 2013-03-15 AU AU2013298915A patent/AU2013298915B2/en active Active
- 2013-03-15 SI SI201331652T patent/SI2879702T1/sl unknown
- 2013-03-15 KR KR1020157005085A patent/KR102264852B1/ko active IP Right Grant
- 2013-03-15 CA CA3158572A patent/CA3158572A1/en active Pending
- 2013-03-15 EP EP13717721.8A patent/EP2879702B9/en active Active
- 2013-03-15 CN CN201380040909.3A patent/CN104540520B/zh active Active
- 2013-03-15 BR BR112015002131-0A patent/BR112015002131B1/pt active IP Right Grant
- 2013-03-15 KR KR1020227028479A patent/KR20220119527A/ko not_active Application Discontinuation
-
2015
- 2015-01-15 IL IL236744A patent/IL236744B/en unknown
- 2015-01-30 MX MX2023003746A patent/MX2023003746A/es unknown
- 2015-01-30 MX MX2019000933A patent/MX2019000933A/es unknown
- 2015-06-25 HK HK15106038.4A patent/HK1205459A1/xx unknown
-
2016
- 2016-10-14 US US15/294,480 patent/US9717787B2/en active Active
-
2017
- 2017-07-28 US US15/662,382 patent/US10124058B2/en active Active
-
2018
- 2018-11-09 US US16/185,125 patent/US10532094B2/en active Active
-
2020
- 2020-01-09 US US16/737,969 patent/US10946089B2/en active Active
- 2020-01-21 CY CY20201100050T patent/CY1122717T1/el unknown
-
2021
- 2021-03-15 US US17/202,230 patent/US20210196814A1/en not_active Abandoned
-
2023
- 2023-07-18 JP JP2023116634A patent/JP2023139095A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122717T1 (el) | Ανασυνδυασμενος τροποπoiημενος ιος της δαμαλιτιδας της αγκυρας (mva) ως εμβολιο εναντι του αναπνευστικου συγκυτιακου ιου (rsv) | |
CY1121528T1 (el) | Ανασυνδυασμενοι φορεις ερπητοϊου gallid 3 (mdv οροτυπου 2) που εκφραζουν αντιγονα παθογονων των πτηνων και χρησεις αυτων | |
EA201491752A1 (ru) | Вакцина против rsv | |
CY1123181T1 (el) | Υποκινητης pr13.5 για ισχυρες αποκρισεις τ-κυτταρων και αντισωματων | |
BR112018070323A2 (pt) | vacina contra rsv | |
CY1118090T1 (el) | Αντιγονα ανασυνδυασμενου rsv | |
EA201492110A1 (ru) | Вакцины против впг-2 | |
DK1881845T3 (da) | Nipah-virusvacciner | |
MX360415B (es) | Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos. | |
WO2012021730A3 (en) | Respiratory syncytial virus (rsv) vaccine | |
MX2019003682A (es) | Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas. | |
MX2017016273A (es) | Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante. | |
EA201791957A1 (ru) | Маркерная система, в частности, для экспрессируемых бакуловирусом субъединичных антигенов | |
EA201790296A1 (ru) | Вакцина в виде рекомбинантного вектора на основе птичьего аденовируса серотипа 9 | |
EP2552490A4 (en) | INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF | |
EA201990719A1 (ru) | Новые промоторы | |
BR112012029633A8 (pt) | Vetores do parapoxvírus contendo antígeno do vírus da raiva. | |
ES2689797T3 (es) | Vacuna de virus Sendai modificado y vector para la obtención de imágenes | |
MX2019007924A (es) | Vacunas contra la influenza. | |
MX2010007876A (es) | Vectores virales recombinantes y composicion de vacuna para leishmaniasis. | |
PH12014502086B1 (en) | Vaccine against rsv | |
EA201992602A3 (ru) | Вакцины против впг-2 | |
EA201790506A1 (ru) | Филовирусная вакцина на основе рекомбинантного модифицированного вируса осповакцины анкара (mva) | |
MX2010003505A (es) | Vacuna recombinante de vector viral inactivado. |